NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Shares of Henry Schein split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has initiated a stock repurchase plan on Tuesday, September 19th 2017, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 6.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings results on Monday, August, 6th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.01 by $0.03. The firm had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.31 billion. Henry Schein had a net margin of 3.15% and a return on equity of 20.40%. The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, November 5th 2018. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Monday, August, 6th. The company provided earnings per share guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus estimate of $4.11.

19 analysts have issued 12-month price objectives for Henry Schein's shares. Their predictions range from $66.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $82.7222 in the next year. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Henry Schein saw a decline in short interest in September. As of September 14th, there was short interest totalling 16,020,723 shares, a decline of 7.3% from the August 31st total of 17,291,234 shares. Based on an average trading volume of 1,103,270 shares, the short-interest ratio is presently 14.5 days. Approximately 10.6% of the shares of the stock are short sold. View Henry Schein's Current Options Chain.

Some companies that are related to Henry Schein include Boston Scientific (BSX), HCA Healthcare (HCA), Illumina (ILMN), Humana (HUM), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), BEXIMCO PHARMAC/S GDR REGS (BXP), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Edwards Lifesciences (EW), Actelion (ALIOF) and ESSILOR Intl S/S (ESLOY).

Henry Schein's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Longview Partners Guernsey LTD (8.92%), Swedbank (1.32%), Fenimore Asset Management Inc. (0.36%), Davis R M Inc. (0.29%), Bank of Montreal Can (0.27%) and Riverbridge Partners LLC (0.27%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Swedbank, Davis R M Inc., Riverbridge Partners LLC, Neville Rodie & Shaw Inc., Gateway Investment Advisers LLC, Texas Permanent School Fund and Laurel Grove Capital LLC. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek and Paul Brons. View Insider Buying and Selling for Henry Schein.

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, CHURCHILL MANAGEMENT Corp, Andra AP fonden, Contravisory Investment Management Inc., Nisa Investment Advisors LLC, We Are One Seven LLC, Jaffetilchin Investment Partners LLC and Tandem Investment Advisors Inc.. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $82.04.

Henry Schein has a market capitalization of $12.63 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]